Astellas Pharma Common Stock

As of the most recent data (June 2026), ALPMY shows a common stock of $100B. That compares with $100B in the prior-year period — down 0.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALPMY's common stock is now $100B (was $100B) — a 0.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Astellas Pharma is outperforming or lagging.

Tracking ALPMY's common stock over time shows whether Astellas Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $100B That compares with $100B in the prior-year period — down 0.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Astellas Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $100B) with ownership activity and broader fundamentals.

Astellas Pharma's common stock is $100B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.